GenScript Biotech
Corporate brand
UnclaimedGenScript Biotech is a China-based biotechnology company providing life-science research products, services, contract development and manufacturing, cell-therapy capabilities, and industrial biotechnology products. GenScript is a life-sciences company offering research products and custom services including gene synthesis, protein, RNA, and genome-editing solutions.
Last updated November 4, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
GenScript Biotech Corporation, commonly known as GenScript, is a biotechnology company founded in New Jersey in 2002 by Fangliang Zhang, Ye Wang, and Luquan Wang. The company established a research and production base in Nanjing in 2004 and developed into a multinational life-science group headquartered in Nanjing, China. Its business is focused on supplying tools, products, and services used in biological research, drug discovery, biopharmaceutical development, and industrial biotechnology. The company operates through four principal platforms: a contract development and manufacturing organization platform, a life-science services and products platform, an integrated cell-therapy platform, and an industrial synthetic-products platform. These activities span research reagents and services, gene and protein-related products, biological-process development, manufacturing support, and therapeutic cell-therapy programs. Its principal subsidiaries and affiliated businesses include Legend Biotech, ProBio Technology, and Bestzyme. GenScript also acquired CustomArray, expanding its capabilities in synthetic biology and research products. GenScript expanded internationally during the 2010s, establishing operations or subsidiaries in markets including Japan, the United States, Singapore, the United Kingdom, and the Netherlands. It raised a reported $15 million investment from KPCB China Fund in 2009 and listed on the Hong Kong Stock Exchange in 2015. Its biotechnology activities subsequently moved beyond research supply into advanced therapeutic development and manufacturing. Legend Biotech collaborated with Janssen Biotech on CAR-T therapies, while ProBio developed as a platform for biopharmaceutical development and manufacturing services. A major development in the group’s therapeutic portfolio was the advancement of the CAR-T therapy later marketed as Carvykti, developed by Legend Biotech and Janssen Biotech. The treatment received United States Food and Drug Administration approval in 2022 for certain adult patients with multiple myeloma. GenScript also participated in the development of cPass, a serology test created with Duke-NUS Medical School for detecting neutralizing antibodies associated with COVID-19; the test received US FDA emergency use authorization in 2020. GenScript has continued to invest in production and international infrastructure, including a protein and gene manufacturing facility in Singapore opened in 2022. In 2021, GenScript and its subsidiary ProBio received Series A funding from Hillhouse Capital. In 2023, Legend Biotech entered an out-licensing agreement with Novartis covering CAR-T candidates directed at DLL3, including LB2102. The agreement included reported upfront and potential milestone payments, together with tiered royalties. The company is led through a rotating chief executive structure; Shao Weihui is identified as the current rotating chief executive officer and has also served as chief operating officer and party committee secretary. GenScript’s identity is therefore that of an integrated biotechnology platform rather than a single therapeutic brand: it combines research products, outsourced biopharmaceutical development, manufacturing, industrial biotechnology, and cell-therapy assets across a global operating network. GenScript presents itself as a provider of products and services for life-science research and development. Its official website describes customizable and tailor-made research solutions, backed by Ph.D.-level customer support. Its service areas include gene services, protein services, mRNA services, and CRISPR services, while its product catalogue includes bioreagents, instruments, and kits. Gene-related offerings include gene synthesis and molecular biology services. The company promotes FLASH Gene as a gene-to-plasmid service with a stated four-business-day turnaround, and describes customized gene synthesis solutions for sequences up to 200 kb. Its protein portfolio includes protein expression and antibody-related capabilities. The website also presents RNA services spanning mRNA, circular RNA, self-amplifying RNA, and lipid nanoparticle formulation. GenScript describes its RNA platform as supporting work from early discovery through preclinical, IND, and early-phase clinical studies. It says that the platform integrates RNA design and synthesis with LNP formulation, and offers related products and services such as RNA quality-control analysis and its GenScript Cap technology. Its website also lists research applications including cell therapy, gene therapy, antibody drug development, and vaccine development. The supplied official-site material positions GenScript around customizable solutions, technical expertise, service integration, speed, and research support. It references customers and delivery in global markets but does not establish the company’s founding details, headquarters, ownership, leadership, or listed status. Those details are therefore not specified here. The company is led through a rotating CEO structure; Shao Weihui has been identified as the current rotating CEO and previously served as chief operating officer and party secretary. GenScript’s identity is therefore that of an integrated biotechnology platform rather than a single therapeutic brand: it combines research products, outsourced biopharmaceutical development, manufacturing, industrial biotechnology, and cell-therapy assets across a global operating network. On the research-services side, GenScript presents itself as a provider of customizable life-science solutions with Ph.D.-level customer support, spanning gene services, protein services, mRNA services, and CRISPR services, alongside a product catalogue of bioreagents, instruments, and kits. Its gene-related offerings include gene synthesis and molecular biology services, including FLASH Gene, a gene-to-plasmid service with a stated four-business-day turnaround, and customized gene synthesis for sequences up to 200 kb. Its protein portfolio includes protein expression and antibody-related capabilities, while its RNA services span mRNA, circular RNA, self-amplifying RNA, and lipid nanoparticle formulation, supporting work from early discovery through preclinical, IND, and early-phase clinical studies. The company also offers RNA quality-control analysis and its GenScript Cap technology, and lists research applications including cell therapy, gene therapy, antibody drug development, and vaccine development.
History
GenScript was established in New Jersey in 2002 by Fangliang Zhang, Ye Wang, and Luquan Wang. The company initially focused on life-science research applications and subsequently built a larger research and production presence in China. In 2004, it established a base in Nanjing, which later became the location of its headquarters and a central part of its operating network. In 2009, GenScript secured a reported $15 million investment from KPCB China Fund. The company continued its international development in the following years, opening a Japanese subsidiary in 2011. In 2013, it established Bestzyme, an industrial biotechnology business. Legend Biotech was founded in 2014 as another subsidiary focused on therapeutic biotechnology and cell therapy. GenScript became publicly listed on the Hong Kong Stock Exchange in 2015. The group’s therapeutic ambitions became more prominent in 2017. Nanjing Legend received approval from China's former China Food and Drug Administration for an investigational new drug application relating to a blood-cancer treatment and permission to conduct clinical trials. During the same year, Legend Biotech USA and Legend Biotech Ireland entered into a collaboration with Janssen Biotech concerning CAR-T treatments in the United States and China. GenScript also completed the full acquisition of CustomArray, broadening its research-product and synthetic-biology capabilities. In 2020, GenScript launched ProBio as a subsidiary focused on biopharmaceutical development and manufacturing. It also worked with Duke-NUS Medical School on cPass, a serology test designed to detect neutralizing antibodies associated with SARS-CoV-2 infection. The US FDA granted the test emergency use authorization on November 6, 2020. Legend Biotech was separately listed on the Nasdaq under the symbol LEGN during this period. GenScript’s cell-therapy business reached a major regulatory milestone in 2022 when Carvykti, developed by Legend Biotech and Janssen Biotech, received US FDA approval for the treatment of certain adults with multiple myeloma. GenScript also opened a Singapore facility for protein and gene manufacturing, reinforcing its regional production footprint. In 2021, GenScript and ProBio received Series A funding from Hillhouse Capital. In 2023, Legend Biotech signed an out-license agreement with Novartis for CAR-T candidates targeting delta-like ligand 3, or DLL3. The agreement included LB2102, a candidate for large-cell neuroendocrine carcinoma, and provided for an upfront payment, potential clinical, regulatory, and commercial milestones, and tiered royalties as described in the cited reference material. The company has continued to operate as a diversified biotechnology group with four broad platforms: CDMO services; life-science products and services; integrated cell therapy; and industrial synthetic products. Its geographic presence extends beyond China and the United States to countries including Singapore, Japan, the United Kingdom, and the Netherlands. In 2024, the company became the subject of questions from a US congressional committee concerning possible Chinese government influence over GenScript and several subsidiaries. The committee requested intelligence briefings; the reference material does not establish a final finding of wrongdoing. The supplied evidence establishes GenScript as an active life-sciences research and development provider, but it does not document the company’s founding, early corporate history, headquarters, ownership, or leadership. Accordingly, a dated corporate chronology cannot be established from the available sources. The current official-site material describes a portfolio spanning gene, protein, RNA, and CRISPR services, alongside life-science research products such as bioreagents, instruments, and kits. The company’s service offering includes gene synthesis and molecular biology, protein services, mRNA services, and genome-editing-related services. Its product and service pages describe applications in cell therapy, gene therapy, antibody drug development, and vaccine development. The gene-synthesis page promotes FLASH Gene as a four-business-day gene-to-plasmid offering. It describes the service as combining DNA synthesis, cloning, and plasmid preparation, and notes that the company offers customized solutions for larger gene sequences. The evidence also refers to the GenGenius automation platform and GenBrick as part of its gene-related offering. The RNA services page describes an integrated platform covering mRNA, circular RNA, self-amplifying RNA, and LNP formulation. It states that the platform is intended to support work from early discovery through preclinical, IND, and early-phase clinical studies. The page also names GenScript Cap technology and related RNA services, including synthesis and quality-control analysis. These sources provide a snapshot of the company’s current service and product positioning rather than a complete history. They do not supply dated founding, merger, acquisition, listing, leadership, or geographic-expansion events, so such milestones are not inferred. On the research-services side, GenScript presents itself as a provider of products and services for life-science research and development, describing customizable and tailor-made research solutions backed by Ph.D.-level customer support. Its service areas include gene services, protein services, mRNA services, and CRISPR services, while its product catalogue includes bioreagents, instruments, and kits. Gene-related offerings include gene synthesis and molecular biology services; the company promotes FLASH Gene as a gene-to-plasmid service with a stated four-business-day turnaround and describes customized gene synthesis solutions for sequences up to 200 kb. Its protein portfolio includes protein expression and antibody-related capabilities. The website also presents RNA services spanning mRNA, circular RNA, self-amplifying RNA, and lipid nanoparticle formulation, and describes its RNA platform as supporting work from early discovery through preclinical, IND, and early-phase clinical studies. The platform integrates RNA design and synthesis with LNP formulation and offers related products and services such as RNA quality-control analysis and its GenScript Cap technology. Its website also lists research applications including cell therapy, gene therapy, antibody drug development, and vaccine development. The company has stated that it has been the largest gene provider in the US since 2008, and it has announced the GenScript Life Science Research Grant 2026 with a funding pool of up to $1.5 million.
- 2024
US congressional security inquiry
[1]A US House committee requested intelligence briefings regarding possible undue Chinese government influence over GenScript and several subsidiaries.
- 2023
Novartis CAR-T out-license agreement
[1]Legend Biotech agreed to license DLL3-directed CAR-T candidates, including LB2102, to Novartis for development and manufacturing.
- 2022
Carvykti approved in the United States
[1]Carvykti, developed by Legend Biotech and Janssen Biotech, received US FDA approval for certain adults with multiple myeloma.
- 2022
Singapore manufacturing facility opened
[1]GenScript opened a Singapore facility for protein and gene manufacturing.
- 2021
Hillhouse Capital funding
[1]GenScript and ProBio received Series A funding from Hillhouse Capital.
- 2020
ProBio launched
[1]GenScript launched ProBio as a biopharmaceutical development and manufacturing platform.
- 2020
cPass receives emergency authorization
[1]The cPass serology test developed with Duke-NUS Medical School received US FDA emergency use authorization.
- 2017
Legend Biotech advances CAR-T collaboration
[1]Nanjing Legend obtained Chinese investigational-drug approval for a blood-cancer treatment, while Legend Biotech entities entered a CAR-T collaboration with Janssen Biotech.
- 2017
CustomArray acquired
[1]GenScript completed the full acquisition of CustomArray.
- 2015
Hong Kong listing
[1]GenScript became publicly listed on the Hong Kong Stock Exchange.
Products and positioning
An integrated biotechnology and life-science platform connecting research tools and services with biopharmaceutical development, contract manufacturing, cell therapy, and industrial synthetic biology. A life-sciences research and development solutions provider emphasizing customizable services, technical expertise, integrated platforms, and turnaround speed.
Life-science research services
Gene synthesis and genetic engineering services
GenScript provides gene-related research services used to design, synthesize, modify, and analyze genetic material. These capabilities support academic research, biotechnology development, protein engineering, synthetic biology, and drug-discovery workflows. The offering is part of the company’s broader life-science services and products platform rather than a single consumer-facing product.
Life-science products and services
Protein, antibody, and reagent services
GenScript supplies research-oriented biological products and services involving proteins, antibodies, nucleic acids, and related experimental workflows. These offerings are intended for laboratories, biotechnology companies, and pharmaceutical researchers working in immunology, molecular biology, protein science, and therapeutic discovery.
Contract development and manufacturing · 2020
ProBio CDMO services
ProBio provides outsourced development and manufacturing support for biopharmaceutical programs. Its role within the GenScript group includes helping customers move from early biological development toward process development and manufacturing. The platform complements GenScript’s research tools and Legend Biotech’s therapeutic-development activities.
Cell therapy
CAR-T cell-therapy programs
Through Legend Biotech, GenScript participates in the development of chimeric antigen receptor T-cell therapies. The group’s collaboration with Janssen Biotech produced Carvykti, an approved therapy for certain adults with multiple myeloma, and Legend has also advanced additional CAR-T candidates, including DLL3-directed programs.
Serology test · 2020
cPass
cPass is a serology test developed by GenScript in collaboration with Duke-NUS Medical School to detect neutralizing antibodies associated with SARS-CoV-2. The test received emergency use authorization from the US FDA in 2020, making it one of GenScript’s most visible pandemic-era diagnostic products.
Industrial biotechnology · 2013
Bestzyme industrial enzyme products
Bestzyme represents GenScript’s industrial synthetic-products platform. Its activities center on industrial biotechnology and enzyme-related products, serving applications outside conventional laboratory research and therapeutic development.
FLASH Gene
A gene-to-plasmid synthesis service promoted with a four-business-day turnaround.
IVT RNA Production Services
RNA services covering mRNA, circular RNA, self-amplifying RNA, and LNP formulation.
TurboCHO Protein Expression Kit
A protein expression kit featured on the GenScript homepage.
Controversies
2020
Founder Zhang Fangliang arrested on suspicion of smuggling
In 2020, GenScript chairman Zhang Fangliang was placed under residential surveillance at a location designated by customs, and was later arrested on suspicion of smuggling goods prohibited from import and export by the state. He resigned from related roles at GenScript and Legend Biotech, and the share price fell continuously. Outside speculation linked the case to illegal export of human genetic resources, and the company did not disclose the specific reason. In May 2022, the Zhenjiang Municipal People’s Procuratorate decided not to prosecute, and Zhang Fangliang resumed his role as non-executive director.
Brand decisions
2023
Out-license DLL3-directed CAR-T programs to NovartisM&ABackground
Legend Biotech was developing CAR-T candidates directed at delta-like ligand 3, including LB2102 for large-cell neuroendocrine carcinoma.
Action taken
Legend Biotech signed an out-license agreement with Novartis covering development and manufacturing of the relevant CAR-T candidates.
Aftermath
The cited terms included a $100 million upfront payment, potential clinical, regulatory, and commercial milestone payments of up to $1.01 billion, and tiered royalties.
Upfront payment and potential milestone payments. $100 million upfront; up to $1.01 billion in potential milestone payments plus tiered royalties (Agreement announced in November 2023)
2022
Expand Singapore manufacturing capacityStrategyBackground
GenScript was expanding its international production footprint and developing capabilities in protein and gene manufacturing.
Action taken
The company opened a protein and gene manufacturing facility in Singapore.
Aftermath
The facility strengthened GenScript’s regional manufacturing infrastructure outside mainland China.
2020
Launch of ProBioProduct launchBackground
GenScript sought to broaden its business beyond research products and services into outsourced biopharmaceutical development and manufacturing.
Action taken
The company launched ProBio as a dedicated biopharmaceutical development and manufacturing subsidiary.
Aftermath
ProBio subsequently became part of the group’s CDMO platform and received Series A funding with GenScript from Hillhouse Capital in 2021.
2017
Expand into therapeutic cell therapyStrategyBackground
GenScript had developed Legend Biotech as a therapeutic biotechnology subsidiary, and its blood-cancer program received Chinese investigational-drug approval in 2017.
Action taken
Legend Biotech entities entered a collaboration with Janssen Biotech to develop and share CAR-T treatments in the United States and China.
Aftermath
The collaboration contributed to the development of Carvykti, which later received US FDA approval in 2022.
Recent events
Reported
GenScript launches GenWand dsDNA service[9]
GenScript announced the launch of its GenWand Double-Stranded DNA service for manufacturing CRISPR knock-in homology-directed repair templates in T cell engineering.
Reported
GenScript opens automated gene synthesis facility in New Jersey[10]
GenScript announced that it had opened a more than 50,000-square-foot facility near its U.S. headquarters in Piscataway, New Jersey, for highly automated gene synthesis and plasmid preparation services. The site represents a 10-fold increase in capacity.
Reported
GenScript receives Asia-Pacific Best Contract Research Organization Award[11]
GenScript received the Best Contract Research Organization Award at the 4th Annual Asia Pacific Bioprocessing Excellence Awards Ceremony held on March 16, 2021.
GenScript releases 2020 earnings forecast[12]
GenScript released its 2020 earnings forecast. It expected adjusted net profit for its non-cell therapy business of approximately $41.1 million to $47.9 million, up 90.3%–121.8% from the same period in 2019, and an adjusted loss for its cell therapy business of approximately $202.4 million to $234.4 million.
Reported
Innatoss launches public SARS-CoV-2 antibody testing service[13]
Innatoss Laboratories announced a public SARS-CoV-2 neutralizing-antibody testing service in Europe using GenScript's cPass kit.
Reported
GenScript launches the GenScript ProBio brand[14]
At its forum on July 17, GenScript announced the integration and upgrade of its existing CDMO platform and released the GenScript ProBio brand as its independent CDMO business brand.
Reported
GenScript releases 2019 annual results[15]
GenScript released its 2019 annual results on March 27, reporting revenue of about US$273 million, up 18.4% year over year, and gross profit of about US$180 million, up 13.8%.
Reported
GenScript sponsors Mingdao High School iGEM team[16]
GenScript sponsored project expenses and research materials for Mingdao High School's iGEM team, and provided technical support, according to the article.
- Unconfirmed
Genescript receives two industry honors[17]
Genescript received the titles “Leading Enterprise in the Pharmaceutical and Health Industry” and “Top 100 Enterprise” on the 2019 China Digital Service and Outsourcing Leading Enterprises list.
Reported
GenScript announces research-support collaboration for Ultra-safe Cell project[18]
GenScript announced that it would provide Harvard University scientist George Church with research support, including DNA synthesis services, for the Ultra-safe Cell project.
Sources23 sources
- 1GenScript Biotechen.wikipedia.org
- 2GenScript - Scripting Possibilitiesgenscript.com
- 3IVT RNA Production Servicesgenscript.com
- 4FLASH Gene & Gene Synthesis - 4-Day Gene to Plasmidgenscript.com
- 5GenScript Productsgenscript.com
- 6Founder Zhang Fangliang arrested on suspicion of smugglingthepaper.cn
- 7Founder Zhang Fangliang arrested on suspicion of smugglingnbd.com.cn
- 8Founder Zhang Fangliang arrested on suspicion of smugglingm.medvalley.cn
- 9金斯瑞推出 GenWand dsDNA 服务prnewswire.com
- 10GenScript在新泽西州启用自动化基因合成设施prnewswire.com
- 11GenScript获得亚太地区最佳合同研究组织奖prnewswire.com
- 12金斯瑞发布2020年度业绩预告sc.stock.cnfol.com
- 13Innatoss推出面向公众的新冠中和抗体检测服务prnewswire.com
- 14金斯瑞发布GenScript ProBio品牌prnasia.com
- 15金斯瑞发布2019年全年业绩finance.sina.com.cn
- 16金斯瑞赞助明道中学iGEM团队chinatimes.com
- 17金斯瑞荣获两项行业称号hy.stock.cnfol.com
- 18GenScript宣布为Ultra-safe Cell项目提供研究支持prnewswire.com
- 19金斯瑞荣获“医药健康行业领军企业”及“百强企业”称号finance.sina.com.cn
- 20金斯瑞生物科技发布2021年度中期业绩prnasia.com
- 21GenScript Biotech Reports Full Year 2020 Financial Results and Business Resultsprnewswire.com
- 22GenScript Partners with Harvard University to Develop Ultra-safe Cells Resistant to Natural Virusesbiospace.com
- 23Innatoss Laboratories Launches Neutralizing Antibody Public Testing Service For SARS-CoV-2 In Europe Using GenScript's cPass™ Kitlaboratorynetwork.com
Cite this profile: Cite the canonical profile. /brand-wiki/genscript-biotech · Editorial policy · How profiles are compiled